DBV Technologies (DBVT) Return on Capital Employed (2015 - 2026)
DBV Technologies (DBVT) reported Return on Capital Employed of 84.91% for Q1 2026, up 56177.0% year-over-year from N/an in Q1 2025, and up 34.11% on a QoQ basis from 128.87% in Q4 2025.
DBV Technologies (DBVT) has 10 years of Return on Capital Employed data on file, last reported at 84.91% in Q1 2026.
- Quarterly Return on Capital Employed rose 56177.0% year-over-year to 84.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84.91% (up 56177.0% YoY) and the FY2025 annual result came in at 160.4%, down 3529.0% from the prior year.
- Return on Capital Employed climbed to 84.91% in Q1 2026 per DBVT's latest filing, from 128.87% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.27% in Q3 2022 and bottomed at 646.68% in Q1 2025.
- The 5-year median for Return on Capital Employed is 80.8% (2022), against an average of 131.18%.
- The widest annual swing landed in 2025, when Return on Capital Employed sank 58592 bps; it then soared 56177 bps in 2026.
- Tracing DBVT's Return on Capital Employed over 5 years: stood at 44.37% in 2022, then declined by 16 bps to 51.28% in 2023, then plunged by 371 bps to 241.78% in 2024, then surged by 47 bps to 128.87% in 2025, then soared by 34 bps to 84.91% in 2026.
- Per Business Quant, the three latest DBVT Return on Capital Employed figures stand at 84.91% (Q1 2026), 128.87% (Q4 2025), and 162.43% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -84.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.91% |
| Dec 31, 2025 | -128.87% |
| Sep 30, 2025 | -162.43% |
| Jun 30, 2025 | -256.25% |
| Mar 31, 2025 | -646.68% |
| Dec 31, 2024 | -241.78% |
| Sep 30, 2024 | -143.93% |
| Jun 30, 2024 | -90.19% |
| Mar 31, 2024 | -60.76% |
| Dec 31, 2023 | -51.28% |
| Sep 30, 2023 | -59.54% |
| Jun 30, 2023 | -53.31% |
| Mar 31, 2023 | -48.82% |
| Dec 31, 2022 | -44.37% |
| Sep 30, 2022 | -30.27% |
| Jun 30, 2022 | -45.91% |
| Mar 31, 2022 | -80.80% |
| Dec 31, 2021 | -77.39% |
| Sep 30, 2021 | -82.46% |
| Jun 30, 2021 | -75.85% |
| Mar 31, 2021 | -70.80% |
| Sep 30, 2019 | -168.33% |
| Jun 30, 2017 | -35.41% |
| Jun 30, 2016 | -30.00% |
| Dec 31, 2015 | -27.29% |